Jeffrey has worked in many different executive roles in his 30 years within the pharmaceutical and biotechnology industries. This started with his experience at Sandoz (now Novartis) and Glaxo in the UK where he worked on Salbutamol (Ventolin®), the first selective beta agonist for respiratory disease. He then came to the United States and worked for Marion Merrell Dow in their oncology and immunology programs. This included the first clinical compound as an aromatase inhibitor for breast cancer and cumulated with his work on Allegra®, a non-sedating antihistamine. Jeff then joined the biotechnology arena in San Diego where he has discovered and developed multiple innovative small molecule drug candidate’s that are currently in clinical trials around the world for auto-immune diseases and cancer. This includes Quarfloxin for solid tumors, the kinase inhibitor CX-4945 for liquid tumors, CX-5461 as an oncology pol. II inhibitor, CM-2489 for psoriasis and CM-4621 for pancreatitis. He has a BSc, PhD and Post-Doctoral fellowship from Manchester and Oxford Universities and a M.B.A. from The Ohio State University.